Effect of SynagisⓇ (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants

Effect of SynagisⓇ (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants

Purpose : The aim of this study was to determine the efficacy of Synagis&amp;#9415; (palivizumab) in reducing the respiratory syncytial virus (RSV) readmission rate in very low birth weight infants (VLBWI ) and the subgroup that showed the most effective vaccination....

Full description

Bibliographic Details
Main Authors:	Soo Kyoung Park, Yu Jin Jung, Hye Soo Yoo, So Yoon Ahn, Hyun Joo Seo, Seo Heui Choi, Myo Jing Kim, Ga Won Jeon, Soo Hyun Koo, Kyung-Hoon Lee, Yun Sil Chang, Won Soon Park
Format:	Article
Language:	English
Published:	Korean Pediatric Society 2010-03-01
Series:	Korean Journal of Pediatrics
Online Access:	http://www.kjp.or.kr/upload/2010530312-20100434155234.PDF

Similar Items

Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
by: Andreea Calomfirescu-Avramescu, et al.
Published: (2025-02-01)

Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands
by: Rutger M. Schepp, et al.
Published: (2023-12-01)

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro
by: Envera Lekic, et al.
Published: (2024-05-01)

The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma
by: Hannah Ora Hasson, et al.
Published: (2024-11-01)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
by: Asunci&oacute;n Mej&iacute;as, et al.
Published: (2008-09-01)

Palivizumab prophylaxis during respiratory syncytial virus outbreak in the neonatal intensive care unit
by: Serdar Alan, et al.
Published: (2013-04-01)

Respiratory Morbidity in Prematurely Born Children Receiving Palivizumab Prophylaxis of Respiratory Syncytial Virus Disease
by: Milena Bjelica, et al.
Published: (2024-04-01)

Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants
by: Swiss Medical Weekly
Published: (2001-03-01)

The effect of palivizumab prophylaxis on respiratory syncytial virus-associated hospitalizations in infants with congenital diaphragmatic hernia
by: Pei-Lan Shao
Published: (2018-04-01)

Palivizumab prophylaxis during respiratory syncytial virus outbreak in neonatal intensive care unit: author's reply
by: Mehmet Yekta Oncel, et al.
Published: (2013-04-01)

Respiratory Syncytial Virus and Palivizumab: Where are We in 2014?
by: Joan Robinson
Published: (2014-01-01)

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
by: Jennifer Claydon, et al.
Published: (2017-01-01)

Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
by: Suada Heljic, et al.
Published: (2016-02-01)

Analysis of prognostic factors of laparotomy for necrotizing enterocolitis in extremely low birth weight infants
by: Jin Kyu Kim, et al.
Published: (2010-02-01)

Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease
by: Mohammed Hassan A. Mohammed, et al.
Published: (2021-02-01)

Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
by: M. Elhalik, et al.
Published: (2019-01-01)

THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS
by: A. V. Rudakova, et al.
Published: (2012-07-01)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
by: Natividad Viguria, et al.
Published: (2021-06-01)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
by: Bernhard Resch
Published: (2017-09-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
by: Tianzhou Yu, et al.
Published: (2024-03-01)

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants
by: Bosco Paes, et al.
Published: (2024-01-01)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
by: Ana Isabel M. P. Monteiro, et al.
Published: (2014-06-01)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
by: Griffin M Pamela, et al.
Published: (2010-06-01)

A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
by: Hsin Chi, et al.
Published: (2014-01-01)

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation
by: Turti Tatyana V, et al.
Published: (2012-09-01)

PALIVIZUMAB: NEW CAPABILITIES TO PREVENT SEVERE FORMS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN
by: T.V. Kulichenko
Published: (2010-07-01)

PALIVIZUMAB: NEW CAPABILITIES TO PREVENT SEVERE FORMS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN
by: T.V. Kulichenko
Published: (2010-07-01)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
by: Hasindu S. Edirisinghe, et al.
Published: (2023-11-01)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
by: Abushahin A, et al.
Published: (2018-01-01)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
by: Mariana Bueno Manini, et al.

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
by: Antepowicz, A, et al.
Published: (2021)

Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
by: J. L. Grodin, et al.
Published: (2012-01-01)

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
by: Jaime E. Ordóñez, et al.
Published: (2024-04-01)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
by: O'Hagan S, et al.
Published: (2023-09-01)

Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon.
by: Hadi Abou-El-Hassan, et al.
Published: (2019-01-01)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
by: Agata Antepowicz, et al.
Published: (2021-08-01)

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
by: Bernhard Resch, et al.
Published: (2017-04-01)